Summary THJ-2201 is a synthetic cannabinoid based on the indazole structure, and it is believed to function as a potent agonist for the CB1 receptor. This compound has been available for purchase online as a designer drug. Structurally, THJ-2201 is akin to AM-2201, with the central indole ring substituted by an indazole ring. Identifiers IUPAC …
Summary SDB-005 is a synthetic cannabinoid based on the indazole structure and has been made available for purchase online as a designer drug. It is believed to act as an agonist for the CB1 and CB2 cannabinoid receptors. Notably, SDB-005 shares the indazole core with PB-22, but it distinguishes itself by replacing the 8-hydroxyquinoline with …
Summary PX-3, or APP-CHMINACA, is a synthetic cannabinoid rooted in the indazole structure. Developed by Pfizer in 2009, its original purpose was as an analgesic medication, showcasing potential pharmaceutical utility.This compound’s acronym, ‘APP,’ signifies its structural elements: ‘amino,’ ‘phenyl,’ and ‘propanone.’ In late 2014, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported …
Summary PX-2, also recognized as 5F-APP-PINACA, FU-PX, and PPA(N)-2201, represents an indazole-based synthetic cannabinoid that has been available for online purchase under the designation of a designer drug. This compound incorporates a phenylalanine amino acid amide within its structural composition. Identifiers IUPAC name CAS Number 2365471-47-0 ChemSpider 32741702 UNII MJ9UWE9QAR Chemical and physical data Formula …
Summary MN-18, an indazole-based synthetic cannabinoid, acts as an agonist for cannabinoid receptors, featuring Ki values of 45.72 nM at CB1 and 11.098 nM at CB2, alongside EC50 values of 2.028 nM at CB1 and 1.233 nM at CB2, highlighting its affinity for these receptors. This compound has been available online under the guise of …
Summary MDMB-FUBINACA, also referred to as MDMB(N)-Bz-F and FUB-MDMB, stands as an indazole-derived synthetic cannabinoid renowned for its remarkable potency in binding to cannabinoid receptors. It exhibits Ki values of 1.14 nM at CB1 and 0.1228 nM at CB2, with EC50 values of 0.2668 nM at CB1 and 0.1411 nM at CB2, underscoring its robust …
Summary MDMB-CHMINACA, also recognized as MDMB(N)-CHM, is an indazole-derived synthetic cannabinoid renowned for its robust affinity as a CB1 receptor agonist. This compound has gained notoriety as an online designer drug. Originally developed by Pfizer in 2008, MDMB-CHMINACA is among the most potent cannabinoid agonists, boasting an impressive binding affinity of 0.0944 nM at the …
Summary MDMB-4en-PINACA, often erroneously referred to as 5-CL-ADB-A, is an indazole-based synthetic cannabinoid that has gained popularity as an online designer drug. In 2021, the Drug Enforcement Administration (DEA) in the United States reported MDMB-4en-PINACA as the most prevalent synthetic cannabinoid in circulation.[8] Notably, MDMB-4en-PINACA distinguishes itself from 5F-MDMB-PINACA by substituting the 5-fluorophenyl group with …
Summary FAB-144, classified as an indazole-derived synthetic cannabinoid, is believed to exhibit vigorous agonistic activity towards the CB1 receptor. This compound has gained notoriety for its online availability as a designer drug and is the indazole counterpart of XLR-11. Identifiers IUPAC name CAS Number 2180935-79-7 PubChem CID 102135350 ChemSpider 32055552 UNII B9JT6F9X8V Chemical and physical …
Summary CUMYL-THPINACA also recognized as SGT-42, is categorized as an indazole-3-carboxamide-based synthetic cannabinoid. This compound is a robust agonist for cannabinoid receptors, exhibiting approximately 6 times greater selectivity for CB1. Specifically, it boasts an EC50 of 0.1nM for human CB1 receptors and 0.59nM for human CB2 receptors. Identifiers IUPAC name CAS Number 1400742-50-8 PubChem CID …
